Open AccessEGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome
Author(s) -
Andreas Tiefenbacher,
Robert Pirker
Publication year - 2017
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2017.10.02
Subject(s) - medicine , cetuximab , lung cancer , epidermal growth factor receptor , tyrosine kinase , oncology , cancer research , gefitinib , egfr inhibitors , monoclonal antibody , targeted therapy , tyrosine kinase inhibitor , cancer , receptor , antibody , immunology , colorectal cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom